Blood neurofilament light chain and total tau levels at admission predict death in COVID-19 patients

J Neurol. 2021 Dec;268(12):4436-4442. doi: 10.1007/s00415-021-10595-6. Epub 2021 May 10.

Abstract

Background and aims: Patients infected with SARS-CoV-2 range from asymptomatic, to mild, moderate or severe disease evolution including fatal outcome. Thus, early predictors of clinical outcome are highly needed. We investigated markers of neural tissue damage as a possible early sign of multisystem involvement to assess their clinical prognostic value on survival or transfer to intensive care unit (ICU).

Methods: We collected blood from 104 patients infected with SARS-CoV-2 the day of admission to the emergency room and measured blood neurofilament light chair (NfL), glial fibrillary acidic protein (GFAP), ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), and total tau protein levels.

Results: We found that NfL, GFAP, and tau were significantly increased in patients with fatal outcome, while NfL and UCH-L1 in those needing ICU transfer. ROC and Kaplan-Meier curves indicated that total tau levels at admission accurately predict mortality.

Conclusions: Blood neural markers may provide additional prognostic value to conventional biomarkers used to predict COVID-19 outcome.

Keywords: COVID-19; GFAP; Neurofilament light chain; SARS-CoV-2; Tau; UCH-L1.

MeSH terms

  • Biomarkers
  • COVID-19* / mortality
  • Glial Fibrillary Acidic Protein / blood
  • Humans
  • Intermediate Filaments*
  • Neurofilament Proteins / blood*
  • Ubiquitin Thiolesterase / blood
  • tau Proteins / blood*

Substances

  • Biomarkers
  • GFAP protein, human
  • Glial Fibrillary Acidic Protein
  • MAPT protein, human
  • Neurofilament Proteins
  • UCHL1 protein, human
  • tau Proteins
  • Ubiquitin Thiolesterase